There were also inklings of this on December 25th 
In itself, it’s quite a niche area: predicting treatment outcomes for metastatic bladder cancer. They combine Aiforia’s tools and expertise in histology with spatial transcriptomics, which is a map of which genes are expressed in cancer tissue. By combining these, an AI-assisted predictive biomarker is being developed. That is new and the future.
EV+pembro is a chemotherapeutic agent combined with an antibody that targets bladder cancer cells. Pembrolizumab is the world’s best-selling immune activation release agent.
Paige has also collaborated with Dana. Although one has to start somewhere, I would still consider the opportunity given to Aiforia to show what it can do in top-tier research in the US as significant. Various digital pathology models for clinical use are what drive sales. Then there are tools like Aiforia Create, which researchers can use to build and study their own models. It’s a show of confidence in Aiforia’s technology. And it will ultimately lead to sales.